key: cord-1013211-ecnued3k
authors: Zang, Ruochen; Case, James Brett; Gomez Castro, Maria Florencia; Liu, Zhuoming; Zeng, Qiru; Zhao, Haiyan; Son, Juhee; Rothlauf, Paul W.; Hou, Gaopeng; Bose, Sayantan; Wang, Xin; Vahey, Michael D.; Kirchhausen, Tomas; Fremont, Daved H.; Diamond, Michael S.; Whelan, Sean P.J.; Ding, Siyuan
title: Cholesterol 25-hydroxylase suppresses SARS-CoV-2 replication by blocking membrane fusion
date: 2020-06-09
journal: bioRxiv
DOI: 10.1101/2020.06.08.141077
sha: 0ef401f8d309d6cd5e7c840bc82ce816d312bfd8
doc_id: 1013211
cord_uid: ecnued3k

Cholesterol 25-hydroxylase (CH25H) is an interferon-stimulated gene (ISG) that shows broad antiviral activities against a wide range of enveloped viruses. Here, using an ISG screen against VSV-SARS-CoV and VSV-SARS-CoV-2 chimeric viruses, we identified CH25H and its enzymatic product 25-hydroxycholesterol (25HC) as potent inhibitors of virus replication. Mechanistically, internalized 25HC accumulates in the late endosomes and blocks cholesterol export, thereby restricting SARS-CoV-2 spike protein catalyzed membrane fusion. Our results highlight a unique antiviral mechanism of 25HC and provide the molecular basis for its possible therapeutic development.

6 HEK293-hACE2 cells (Fig. 1C ). Unlike IFITM3, CH25H partially retained its antiviral 115 activity and led to reduced VSV-SARS-CoV-2 replication in TMPRSS2-expressing cells 116 (Fig. 3A) . Similarly, wild-type SARS-CoV-2 replication was inhibited by CH25H and 25HC 117 in TMPRSS2 expressing cells (Fig. 3B) . 118 119 We next examined the effect of 25HC on SARS-CoV S and SARS-CoV-2 S mediated 120 membrane fusion, since 25HC blocks cell fusion by Nipah F and VSV G proteins 28 , which 121 are class I and class III viral fusion proteins respectively 34 . We set up an in vitro cell-to-122 cell fusion assay based on the expression of S, GFP, ACE2, and TMPRSS2 in HEK293 123 cells, independently of virus infection (Fig. 3C) . CH25H expression substantially reduced 124 syncytia formation mediated by SARS-CoV-2 S (Fig. 3C) . Although IFITM2 and IFITM3 125 inhibited VSV-SARS-CoV-2 replication ( Fig. 1A-B) , neither prevented S-mediated fusion 126 ( Fig. 3C) , suggesting a distinct mode of antiviral action. Compared to SARS-CoV-2 S, 127 SARS-CoV S induced weaker cell fusion as recently reported 35 , and this process was 128 also blocked by CH25H expression (Fig. 3C) . CH25H also inhibited the syncytia formation 129 induced by Western equine encephalitis virus glycoproteins (class II) and VSV-G (class 130 III) but not reovirus FAST p10 (class IV) fusion protein 36 (Fig. 3D) . To mimic the virus-cell 131 membrane fusion, we co-transfected SARS-CoV-2 S and GFP into donor cells and mixed 132 at 1:1 ratio with ACE2+TMPRSS2+TdTomato co-transfected target cells. As expected, 133 we observed robust syncytia formation under mock conditions (Fig. S3B) . CH25H 134 expression in 'recipient' cells almost completely abolished cell-cell fusion (Fig. S3B) . 135

Exogenous 25HC treatment phenocopied CH25H expression and blocked SARS-CoV-2 7 S mediated syncytia formation ( Fig. S3B and 3E ). Similar to CH25H, 25HC failed to inhibit 137 reovirus FAST p10 mediated fusion (Fig. S3C) . 138

To define the underlying antiviral mechanisms of the IFN-CH25H-25HC axis further, we 140 investigated whether 25HC acts on viral or host membranes. Pre-incubation of VSV-141 SARS-CoV-2 with 10 µM of 25HC for 20 minutes had no effect on infectivity, as opposed 142

to the pre-treatment of host cells (Fig. S4A) . The timing of 25HC addition suggests it 143 primarily acted at the entry stage of VSV-SARS-CoV-2 replication (Fig. S4B) . We are chemically fluorescently labeled cholesterol and 25HC derivatives that have been 154 used to study membrane incorporation and lipid metabolism 38 . C4 TopFluor-25HC 155 retained its anti-VSV-SARS-CoV-2 activity (Fig. S4E) and blocked SARS-CoV-2 S 156 induced syncytia formation (Fig. 4A) , enabling us to use it as a tool to probe the antiviral 157 mechanism of 25HC. After host cell uptake, C4 TopFluor-25HC exhibited punctate 158 patterns and partially co-localized with lysobisphosphatidic acid (LBPA) positive late 159 endosomes and LAMP1 positive lysosomes but not Rab4 positive early and recycling 160 endosomes (Fig. 4B) . Thus, we hypothesized that SARS-CoV-2 depends on endosomal 161 trafficking to establish active replication. Consistent with this hypothesis, ectopic 162 expression of Rab5 and Rab7 dominant negative mutants but not the wild-type proteins 163 significantly decreased VSV-SARS-CoV-2 infection ( Fig. 4C and S4F) . However, Rab5 164 and Rab7 mutants did not have an additive effect with 25HC treatment (Fig. 4C) , further 165 suggesting that 25HC may act at these endosomal vesicles. 25HC is capable of binding 166

Niemann-Pick C1 (NPC1) in vitro 39 , responsible for the egress of cholesterol from the 167 endosomal/lysosomal compartment 40 . 25HC treatment led to an accumulation of 168 intracellular TopFluor-cholesterol (Fig. 4D) . 25HC failed to inhibit the replication of VSV-169 SARS-CoV-2 in serum-free media, in which the infectivity was markedly enhanced (Fig.  170   4E ). Itraconazole (ICZ), a small-molecule inhibitor of NPC1 that elevates endosomal 171 cholesterol levels 41 , mirrored 25HC and inhibited VSV-SARS-CoV-2 replication, more 172 potently than the furin inhibitor decanoyl-RVKR-CMK (Fig. 4F) . The antiviral activity of 173 ICZ also depended on cholesterol and restricted VSV-SARS-CoV-2 in a cell-type 174 independent manner ( Fig. 4F-G) . In contrast to chloroquine and camostat, both of which 175 are antiviral but through different mechanisms, cholesterol-depleting agent methyl-β-176 cyclodextrin 42 reduced SARS-CoV-2 S mediated cell-cell fusion (Fig. 4H) . Either ICZ or 177 25HC also efficiently reduced syncytia formation (Fig. 4H) . Finally, ICZ suppressed the 178 replication of a recombinant SARS-CoV-2 virus that encodes a mNeon-Green reporter 43 179 in Vero-E6 cells (Fig. 4I) . Collectively, our data support a model that 25HC inhibits SARS-180

CoV-2 replication via enhancing endosomal cholesterol levels and blocking virus fusion. and its natural product 25HC restrict S mediated membrane fusion and block SARS-CoV-187 2 entry into host cells. 25HC has shown broad antiviral activity against a wide range of 188 enveloped viruses 26, 28, 49, 50 , and non-enveloped viruses such as reovirus 51 and murine 189 norovirus 52 . However, there seems to be two modes of inhibitory mechanisms involved. 190

One requires a high micromolar concentration and more than 6 hours of pre-incubation 191 time to be effective, in the case of reovirus 51 , pseudorabies virus 53 and human 192 papillomavirus-16 54 , suggesting an indirect metabolic/cellular pathway-mediated 193 mechanism, whereas the other, which includes influenza A virus 26 , Lassa fever virus 55 , 194 hepatitis C virus 56 , and SARS-CoV-2 ( Fig. 2) , functions at a low micromolar/high 195 nanomolar range. Combined with the recent report that apilimod, a PIKfyve kinase 196 inhibitor, effectively inhibits SARS-CoV-2 infection 57 , we confirm that this virus reaches 197 late endosomal compartment for membrane fusion and access to the cytosol, at least in 198 ACE2+TMPRSS2-cells. However, our data of endosomal cholesterol accumulation does 199 not explain how the virus-cell fusion at the plasma membrane driven by SARS-CoV-2 S 200 is effectively blocked by 25HC. A recent study demonstrates that 25HC treatment 201 depletes 'free' cholesterol from the plasma membrane and prevents Listeria 202 dissemination 58 . Treatment of cells with 25HC results in reduced cell surface but 203 enhanced intracellular cholesterol levels (Fig. 4D) . Therefore, it is plausible that 25HC 204 acts at more than one subcellular compartment and that redistribution of cholesterol leads and titrated by focus-forming assay on Vero-E6 cells. Plaque assays were performed in 12 MA104 cells seeded in 6-well plates using an adapted version of the rotavirus plaque 251 assay protocol 67 . The plaque plates were scanned by Amersham Typhoon 5 (GE) and 252 diameters were measured by ImageJ (NIH). 253

Total RNA was extracted from cells using RNeasy Mini kit (Qiagen) and reverse 256 transcription was performed with High Capacity RT kit and random hexamers as 257 previously described 68 . Quantitive PCR was performed using the AriaMX (Agilent) with a 258 25 µl reaction, composed of 50 ng of cDNA, 12.5 µl of Power SYBR Green master mix or 259

Taqman master mix (Applied Biosystems), and 200 nM both forward and reverse primers. 260

All SYBR Green primers and Taqman probes used in this study are listed in Table S1 . were visualized with Clarity ECL substrate and a Biorad Gel Doc XR system. 290

All bar graphs were displayed as means ± SEM. Statistical significance in data Fig. 1E , 293 3B, S1C, S1D, and S2B was calculated by Student's t test using Prism 8.4.2 (GraphPad). 294

Statistical significance in data Fig. 1B, 1C, 1D , 4C, S1G, and S4A was calculated by 295 pairwise ANOVA using Prism 8. Non-linear regression (curve fit) was performed to 296 calculate EC50 values for Fig. 2B and 4I . All data were presented as asterisks (*p≤0.05; 297 **p≤0.01; ***p≤0.001). All experiments other than Fig. 1A were repeated at least three 298 times. Fig. 1A was performed twice with average numbers indicated on the graph. The 299 raw data is included in Dataset S1. were also transfected with TMPRSS2 or treated with trypsin (0.5 µg/ml) or 25HC 461 (10 µM). Cells were harvested for western blot and probed for SARS-CoV-2 S1, 462 S2, and GAPDH protein levels. 

A new coronavirus associated with human respiratory disease in China

Side effects of alpha interferon in chronic hepatitis C

Type 549 I and III interferons disrupt lung epithelial repair during recovery from viral infection

Neutralizing antibody and soluble ACE2 inhibition of a 554 replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is 558 Blocked by a Clinically Proven Protease Inhibitor

Functional assessment of cell entry and receptor 561 usage for SARS-CoV-2 and other lineage B betacoronaviruses

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike 565

Immune signaling by RIG-I-like receptors

LY6E impairs coronavirus fusion and confers immune 571 control of viral disease

Interferon-inducible cholesterol-25-hydroxylase broadly inhibits viral entry 596 by production of 25-hydroxycholesterol

Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells

TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human 603 small intestinal enterocytes

TMPRSS2 activates the human coronavirus 229E for cathepsin-606 independent host cell entry and is expressed in viral target cells in the respiratory 607 epithelium

Distinct patterns of IFITM-mediated restriction of filoviruses, SARS 610 coronavirus, and influenza A virus

SARS-CoV-2 entry factors are highly expressed in nasal epithelial 613 cells together with innate immune genes

Virus and cell fusion mechanisms. Annual review of cell and 616 developmental biology

Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly 619 potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high 620 capacity to mediate membrane fusion

A new class of fusion-associated small transmembrane 623 (FAST) proteins encoded by the non-enveloped fusogenic reoviruses. The EMBO 624 journal 19

IFITM proteins restrict viral membrane hemifusion

A lipid-based partitioning mechanism for selective incorporation of 630 proteins into membranes of HIV particles

Structure of N-terminal domain of NPC1 reveals distinct subdomains for 633 binding and transfer of cholesterol

Niemann-Pick C1 disease gene: homology to mediators of 636 cholesterol homeostasis

Triazoles inhibit cholesterol export from lysosomes by binding to NPC1

Extraction of cholesterol with methyl-beta-cyclodextrin perturbs 643 formation of clathrin-coated endocytic vesicles

An Infectious cDNA Clone of SARS-CoV-2

A CRISPR screen identifies IFI6 as an ER-resident interferon 649 effector that blocks flavivirus replication

Pan-viral specificity of IFN-induced genes reveals new roles for 652 cGAS in innate immunity

A diverse range of gene products are effectors of the type I 655 interferon antiviral response

Restriction of HIV-1 and other retroviruses by 658 TRIM5

GILT restricts the cellular entry mediated by the envelope glycoproteins 661 of SARS-CoV, Ebola virus and Lassa fever virus

Interferon-inducible cholesterol-25-hydroxylase restricts hepatitis C 665 virus replication through blockage of membranous web formation

Interferon-inducible cholesterol-25-hydroxylase inhibits hepatitis C virus 669 replication via distinct mechanisms

Hydroxycholesterol Production by the Cholesterol-25-Hydroxylase Interferon-Stimulated 673

Gene Restricts Mammalian Reovirus Infection

Hydroxycholesterol Inhibits Replication of Murine Norovirus

Cholesterol 25-hydroxylase acts as a host restriction factor on 679 pseudorabies virus replication

25-Hydroxycholesterol and 27-hydroxycholesterol inhibit human rotavirus 682 infection by sequestering viral particles into late endosomes

25-Hydroxycholesterol Inhibition of Lassa Virus Infection 686 through Aberrant GP1 Glycosylation

Identification of Cholesterol 25-Hydroxylase as a Novel Host Restriction 689 Factor and a Part of the Primary Innate Immune Responses against Hepatitis C Virus 690 Infection

Inhibition of PIKfyve kinase 694 prevents infection by EBOV and SARS-CoV-2. bioRxiv

Oxysterols provide innate immunity to bacterial infection by 697 mobilizing cell surface accessible cholesterol

Structure of M(pro) from COVID-19 virus and discovery of its inhibitors

Crystal structure of SARS-CoV-2 main protease provides a basis for 703 design of improved alpha-ketoamide inhibitors

Structure of the RNA-dependent RNA polymerase from COVID-19 virus

Rhesus rotavirus trafficking during entry into 709 MA104 cells is restricted to the early endosome compartment

Characterization of severe acute respiratory syndrome-associated 716 coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry

Entirely plasmid-based reverse genetics system for rotaviruses

Drebrin restricts rotavirus entry by inhibiting dynamin-mediated endocytosis

Rotavirus VP3 targets MAVS for degradation to inhibit type III interferon 728 expression in intestinal epithelial cells

Dynamic expression profiling of 731

Type I and Type III Interferon-stimulated hepatocytes reveals a stable hierarchy of gene 732 expression

STAG2 deficiency induces interferon responses via cGAS-STING pathway 735 and restricts virus infection